Abstract
dc:description.abstractThe tumour suppressor PTEN is frequently lost in advanced prostate cancer leading to over-activation of the PI3K/AKT/mTOR pathway. Therefore targeting of the PI3K signalling with pathway-specific inhibitors has been proposed as a therapeutic strategy. Inhibition of AKT and mTOR kinases in prostate cancer cell lines showed a decrease in cell viability and reduction in phospho-biomarkers expression. Although apoptosis was not induced, a decrease in cell migration and G1 cell growth arrest were observed in LNCaP cells. However, in primary prostate cultures activation of the Ras/MEK/ERK compensatory pathway was observed following treatment with AKTi. Moreover, cell viability was less affected than in cell lines and autophagy was induced following treatment with AKTi. Surprisingly, treatment with a combination of AKTi and MEK1/2 inhibitors (MEK1/2i and RO-512) did not reduce phosphorylation of ERK1/2 in primary prostate cultures, but irreversible growth arrest-senescence, was evident. Additionally, ex vivo treatment of a ‘near-patient’ prostate xenograft with a combination of AKTi and mTORi significantly reduced tumour frequency. These results demonstrate that targeting the PI3K/AKT/mTOR pathway triggers activation of the Ras/MEK/ERK compensatory pathway and therefore blockade of one pathway is not sufficient to treat prostate cancer. This study also highlights the importance of using patient-derived tumour cells in preclinical assessment of new drugs rather than relying solely on cancer cell lines.
Degree
thesis:*- Name dc:type.qualificationname
- Ph.D
- Level dc:type.qualificationlevel
- doctoral
- Grantor dc:publisher.institution
- University of York
- Year dc:date.issued
- 2014
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Butler, Dominika Ewelina
- Advisors dc:contributor.advisor
-
- Maitland, Norman J
- Davies, Barry R
Rights
- Language dc:language.dcterms_iso639_2
- eng
Identifiers
dc:identifier.*- Identifier
- uk.bl.ethos.643655